IL271212A - Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor - Google Patents
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitorInfo
- Publication number
- IL271212A IL271212A IL271212A IL27121219A IL271212A IL 271212 A IL271212 A IL 271212A IL 271212 A IL271212 A IL 271212A IL 27121219 A IL27121219 A IL 27121219A IL 271212 A IL271212 A IL 271212A
- Authority
- IL
- Israel
- Prior art keywords
- administering
- methods
- diabetic patients
- pcsk9 inhibitor
- treating hyperlipidemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517672P | 2017-06-09 | 2017-06-09 | |
US201762532162P | 2017-07-13 | 2017-07-13 | |
EP18305565 | 2018-05-04 | ||
PCT/IB2018/054182 WO2018225041A1 (en) | 2017-06-09 | 2018-06-09 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL271212A true IL271212A (en) | 2020-01-30 |
Family
ID=62815099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL271212A IL271212A (en) | 2017-06-09 | 2019-12-05 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3634469A1 (en) |
JP (2) | JP2020522544A (en) |
KR (1) | KR20200026826A (en) |
CN (1) | CN110913889A (en) |
AU (1) | AU2018280567A1 (en) |
CA (1) | CA3066317A1 (en) |
IL (1) | IL271212A (en) |
MX (1) | MX2019014831A (en) |
TW (2) | TW201904608A (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
AR087305A1 (en) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
MX2018002000A (en) | 2015-08-18 | 2018-06-19 | Regeneron Pharma | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis. |
CN113876956B (en) * | 2020-07-01 | 2023-07-04 | 陈敏 | Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation |
CN114525258A (en) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application |
CN115992138A (en) * | 2021-09-30 | 2023-04-21 | 北京安龙生物医药有限公司 | Targeting oligonucleotides for treating PCSK 9-related diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3672B1 (en) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
AU2015289617B2 (en) * | 2014-07-16 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
CA2955294A1 (en) * | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
MX2018002000A (en) * | 2015-08-18 | 2018-06-19 | Regeneron Pharma | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis. |
-
2018
- 2018-06-08 TW TW107119851A patent/TW201904608A/en unknown
- 2018-06-08 TW TW111142924A patent/TW202310872A/en unknown
- 2018-06-09 CN CN201880037888.2A patent/CN110913889A/en active Pending
- 2018-06-09 JP JP2019567608A patent/JP2020522544A/en active Pending
- 2018-06-09 KR KR1020197038159A patent/KR20200026826A/en not_active IP Right Cessation
- 2018-06-09 AU AU2018280567A patent/AU2018280567A1/en active Pending
- 2018-06-09 EP EP18737034.1A patent/EP3634469A1/en not_active Withdrawn
- 2018-06-09 CA CA3066317A patent/CA3066317A1/en active Pending
- 2018-06-09 MX MX2019014831A patent/MX2019014831A/en unknown
-
2019
- 2019-12-05 IL IL271212A patent/IL271212A/en unknown
-
2023
- 2023-07-07 JP JP2023111915A patent/JP2023123842A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019144346A3 (en) | 2021-10-13 |
MX2019014831A (en) | 2020-02-13 |
AU2018280567A1 (en) | 2020-01-23 |
CN110913889A (en) | 2020-03-24 |
JP2020522544A (en) | 2020-07-30 |
RU2019144346A (en) | 2021-07-09 |
TW202310872A (en) | 2023-03-16 |
JP2023123842A (en) | 2023-09-05 |
TW201904608A (en) | 2019-02-01 |
CA3066317A1 (en) | 2018-12-13 |
EP3634469A1 (en) | 2020-04-15 |
KR20200026826A (en) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271212A (en) | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor | |
IL244995B (en) | Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia | |
IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
EP3368062A4 (en) | Methods for treating craniosynostosis in a patient | |
MX2017004471A (en) | Triazolopyridine compounds and methods for the treatment of cystic fibrosis. | |
PL3169353T3 (en) | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) | |
PL3371165T3 (en) | A btk inhibitor for use in treating cancer | |
IL261420A (en) | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor | |
EP3313514A4 (en) | Positioning device for use in therapeutic treatment | |
WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
EP3862000C0 (en) | Medicine for treating chronic cough | |
HK1252514A1 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
IL227374A0 (en) | Guiding means for administering acupuncture and other healing procedures | |
PL3406258T3 (en) | Medicament for use in treating gout | |
MX2017007245A (en) | Methods of treating fibrosis. | |
EP3391052A4 (en) | Methods of preventing or treating hypoglycemia by administering a gpr119 agonist | |
GB201511595D0 (en) | Medical device for treating a vein | |
IL271456B (en) | Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia | |
PT3167881T (en) | Locally administered ethamsylate as a medicament | |
UA86338U (en) | Method for treating gestational diabetes | |
GB201712192D0 (en) | SmartDepo-(extended-release injections) a promising new drug treatment for addiction | |
IL250080A0 (en) | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) | |
SG10201911565YA (en) | Method for identifying personalized therapeutic strategies for patients affected with a cancer | |
SG10201400824YA (en) | Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds | |
UA92214U (en) | Method for treating diabetic polyneuropathy in patients with diabetes mellitus type 2 |